The Estée Lauder Cos. Looks to Pharmaceutical Industry for New Ingredients
As the Estée Lauder Cos. is looking to bulk up its innovation capabilities, it’s looking to another industry for its latest set of ingredients.
The beauty giant is collaborating with the biotechnology and pharmaceutical company Serpin Pharma, which has been researching anti-inflammatory technologies for 20 years. The company discovered Serine Protease Inhibitors, a class of proteins, which quell inflammation, and Lauder will be researching the proteins’ applications in beauty, as well as other technologies, which will be Lauder’s exclusively.
More from WWD
Innovation is a core tenet of Beauty Reimagined, the strategy unveiled by newly minted chief executive officer Stéphane de La Faverie simultaneously with the company’s latest financial results. At the same time, he unveiled a new organizational structure to best support bringing those innovations to market speedily.
It is understood that Lauder is evaluating applications for Serpin Pharma’s technology across its brand portfolio, which ranges in price point and category from Balmain Beauty, La Mer and Estée Lauder to Aveda and The Ordinary and others.
“This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery,” said Carl Haney, executive vice president of global innovation, research and development at Lauder, in a statement. “In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
Added Cohava Gelber, founder, executive chairperson and chief executive officer of Serpin Pharma, “Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury. We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation.”
Best of WWD
Sign up for WWD's Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.
Solve the daily Crossword
